Skip to main content

Advertisement

Table 2 Cox model distant relapse-free survival (DRFS) analyses in patients with residual disease from the MDACC-based cohort (GSE25066 [19])

From: Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

     Univariate analysis Multivariable analysis
Variables n % 5-yr DRFS HR Lower 95 % Upper 95 % P value HR Lower 95 % Upper 95 % P value
Age, years (cont. variable) 1.0 0.98 1.01 0.590 0.98 0.97 1.01 0.129
Tumor size            
 T0-T2 216 56 % 74 % 1.0 1.0
 T3-T4 173 44 % 61 % 2.1 1.38 3.07 <0.001 1.5 1.16 1.92 0.002
Node status            
 N0 126 32 % 85 % 1.0 1.0
 N1-3 263 68 % 66 % 3.3 1.90 5.71 <0.001 2.9 1.62 5.37 <0.001
ER IHC            
 Positive 129 34 % 78 % 1.0 1.0
 Negative 255 66 % 47 % 4.0 2.69 6.02 <0.001 1.8 0.87 3.56 0.114
PR IHC            
 Positive 175 46 % 79 % 1.0 1.0
 Negative 208 54 % 54 % 3.3 2.15 5.05 <0.001 1.2 0.62 2.13 0.654
HER2 STATUS            
 Negative 373 99 % 68 % 1.0 1.0
 Positive 3 1 % NA 1.1 0.16 8.16 0.900 0.5 0.07 3.65 0.485
Histological grade            
 1 28 8 % 96 % 1.0 1.0
 2 160 44 % 73 % 6.1 0.83 44.43 0.076 2.75 0.36 20.94 0.33
 3 175 48 % 60 % 10.9 1.51 78.73 0.018 2.54 0.33 19.66 0.37
PAM50            
 Luminal A 144 37 % 83 % 1.0 1.0
 Luminal B 90 23 % 74 % 1.8 0.90 3.46 0.097 1.4 0.69 2.82 0.360
 HER2-E 30 8 % 41 % 5.9 3.38 10.30 <0.001 2.7 1.15 6.41 0.023
 Basal-like 102 26 % 48 % 5.3 2.63 10.84 <0.001 2.8 1.19 6.42 0.018
 Normal-like 23 6 % 82 % 1.6 0.55 4.85 0.380
  1. HER2-E, HER2-enriched; pCR, Pathological complete response; ER, Estrogen receptor; PR, Progesterone receptor; IHC, Immunohistochemistry